Pharvaris (NASDAQ:PHVS) Cut to “Sell” at Wall Street Zen

by · The Markets Daily

Wall Street Zen downgraded shares of Pharvaris (NASDAQ:PHVS – Free Report) from a hold rating to a sell rating in a report issued on Saturday.

PHVS has been the topic of several other reports. Oppenheimer boosted their price target on Pharvaris from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, December 4th. Bank of America boosted their target price on shares of Pharvaris from $27.00 to $30.00 and gave the company a “neutral” rating in a report on Thursday, December 4th. Leerink Partners set a $38.00 price objective on Pharvaris in a research note on Wednesday, December 3rd. Guggenheim raised their target price on Pharvaris from $32.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Wednesday, October 8th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $40.56.

View Our Latest Analysis on Pharvaris

Pharvaris Stock Down 2.2%

NASDAQ PHVS opened at $25.09 on Friday. Pharvaris has a 12-month low of $11.51 and a 12-month high of $29.80. The company has a market capitalization of $1.31 billion, a PE ratio of -7.82 and a beta of -2.79. The firm’s 50 day moving average is $25.50 and its 200-day moving average is $23.48.

Pharvaris (NASDAQ:PHVS – Get Free Report) last posted its earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.08. As a group, sell-side analysts expect that Pharvaris will post -2.71 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Palumbo Wealth Management LLC raised its position in Pharvaris by 3.2% during the 2nd quarter. Palumbo Wealth Management LLC now owns 14,549 shares of the company’s stock valued at $256,000 after purchasing an additional 447 shares during the last quarter. TD Asset Management Inc grew its stake in shares of Pharvaris by 27.4% in the second quarter. TD Asset Management Inc now owns 99,510 shares of the company’s stock worth $1,751,000 after acquiring an additional 21,388 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in Pharvaris in the second quarter worth about $57,000. Geode Capital Management LLC lifted its position in Pharvaris by 41.1% in the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after acquiring an additional 15,769 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter.

Pharvaris Company Profile

(Get Free Report)

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

Read More